<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955315</url>
  </required_header>
  <id_info>
    <org_study_id>DGX-J01</org_study_id>
    <nct_id>NCT03955315</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration</brief_title>
  <official_title>A Randomized, Double Blind, Sham-controlled, Multi-center Phase I / II Clinical Study to Assess the Safety and Efficacy of IDCT in Patients With Lumbar Degenerative Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiscGenics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiscGenics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and preliminary efficacy of intradiscal&#xD;
      injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and one sham&#xD;
      control in subjects with chronic low back pain due to Degenerative Disc Disease (DDD) at one&#xD;
      lumbar level from L3 to S1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, randomized, double-blind, sham-controlled, parallel-group, multi-center&#xD;
      study in subjects with single-level, symptomatic lumbar intervertebral disc degeneration (&gt;6&#xD;
      months) and unresponsive to conservative therapy for at least 3 months. The study will&#xD;
      compare single intradiscal injections of high and low dose IDCT with one sham control group.&#xD;
&#xD;
      6 study visits will be completed by all subjects; screening, day 1 (injection day), week 4,&#xD;
      week 12, week 26 and week 52. The subject will be assessed for safety and efficacy utilizing&#xD;
      VAS, ODI and JOABPEQ questionnaires alongside radiographic evaluations. The study will have a&#xD;
      6 month follow-up and a 6 month extension period (total 1 year).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by number of Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the safety and tolerability of a single injection of IDCT in subjects with single-level, symptomatic early to moderate lumbar intervertebral disc degeneration as measured by the incidence of AEs and SAEs observed from Day 1 to week 52</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Pain): Visual Analogue Scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the effect of IDCT on pain as measured by a 0-100mm Visual Analogue Scale (VAS). 0: no pain, 100: worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the effect of IDCT on disability as measured by the Oswestry Disability Index (ODI). Score of 0%: no disability, score of 100%: severely disabled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Pain): JOABPEQ</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the effect of IDCT on pain as measured by JOABPEQ. The range of the score for each domain is from 0 to 100, with higher scores indicating a better condition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radiographic Assessments</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate morphologic changes of treated intervertebral discs using MRI &amp; X-Ray assessments.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with High Dose IDCT (9M cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with Low Dose IDCT (3M cells).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham needle puncture (outside disc)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IDCT</intervention_name>
    <description>Discogenic Cells + Sodium Hyaluronate Vehicle</description>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <other_name>Injectable Disc Cell Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Needle puncture under the muscular layer in front of the intervertebral disc</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of early to moderate degenerative disc disease (DDD), Modified Pfirrmann&#xD;
             Grade 3-7.&#xD;
&#xD;
          -  Chronic low-back pain for at least 6 months prior to screening; unresponsive to at&#xD;
             least 3 months of conservative care.&#xD;
&#xD;
          -  Low-back pain of 40 to 90 mm on the VAS&#xD;
&#xD;
          -  ODI score of 30 to 90.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic involvement of more than one lumbar disc.&#xD;
&#xD;
          -  Other persistent pain/nerve issues including, for example, radiculopathy, leg pain,&#xD;
             Cauda Equine syndrome, etc.&#xD;
&#xD;
          -  Fracture of the spine, previous lumbar spine surgery or previous treatment of the&#xD;
             target disc.&#xD;
&#xD;
          -  Evidence of dynamic instability on lumbar flexion-extension radiographs.&#xD;
&#xD;
          -  Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other&#xD;
             undifferentiated spondyloarthropathy, or Type III Modic changes around the target&#xD;
             disc.&#xD;
&#xD;
          -  Clinical suspicion of a full thickness annular tear at the target disc or other&#xD;
             abnormal disc morphology.&#xD;
&#xD;
          -  Subjects who test positive for communicable disease, have significant systemic&#xD;
             disease, or are prone to infection.&#xD;
&#xD;
          -  Patients who are deemed unsuitable for clinical study participation by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Simpson</last_name>
    <phone>8016644176</phone>
    <email>katie@discgenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Chiba Prefecture</state>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seiji Ohtori, M.D.,Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa Prefecture</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Sakai, M.D, Ph.D.</last_name>
      <phone>+81-463-93-1121</phone>
      <email>daisakai@is.icc.u-tokai.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu city</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Akeda,, M.D.,Ph.D.</last_name>
      <phone>+81-59-232-1111</phone>
      <email>k_akeda@clin.medic.mie-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya university hospital</name>
      <address>
        <city>Showa-ku</city>
        <state>Nagoya</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiro Imagama, M.D, Ph.D</last_name>
      <phone>+81-52-741-2111</phone>
      <email>imagama@med.nagoya-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Kaito, M.D, Ph.D</last_name>
      <phone>+81-6-6879-5111</phone>
      <email>takashikaito@ort.med.osaka-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanashi Prefecture</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirotaka Haro, M.D., Ph.D</last_name>
      <phone>+81-55-273-1111</phone>
      <email>haro@yamanashi.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

